Lilly's Garraway on his way to Roche as veteran Horning set to exit by year-end

This comes just twpo weeks after Garrway left Eli Lilly. (Roche)

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer and head of global product development at Roche in the fall.  

He will fill the large shoes left by the 10-year Roche-Genentech veteran Sandra Horning, who is retiring on the last day of this decade.

In a very brief release, the Swiss Big Pharma said that Garraway comes on board from the start of October, with the two working at the Big Pharma until December 31, when Horning officially leaves.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

Garraway’s name will sound familiar as he was until very recently Eli Lilly’s SVP of oncology R&D, as well as heading up Lilly’s research laboratories novel target research. He will be based in South San Francisco.

RELATED: Eli Lilly cancer chief Levi Garraway replaced by Loxo CEO Josh Bilenker (for now) as Big Pharma rings the changes

He left unexpectedly at the start of the month “to pursue other opportunities” and it turns out it was a pretty big one.

Lilly has been working on cancer drugs and new therapies but with limited success; Roche is one of the largest oncology players on the planet with its older oncology medicines still raking in billions of dollars each year, though it now wants more of a say in the next-gen form of cancer care.

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

The agency also gave the company’s diagnostic, run on the high-throughput Panther Fusion laboratory platform, a green light for pooled testing.

Smith & Nephew has signed up to acquire Integra LifeSciences’ orthopedics business focused on the growing upper and lower extremity markets.